Biopharma
ByCan GSK’s 2025 Approvals and Launches Strengthen Its Vaccines, Respiratory, and Immunology Leadership Into 2026?
Global | January 2026 — GlaxoSmithKline PLC (GSK) achieved key milestones in 2025, with multiple regulatory approvals, product…
Can AstraZeneca’s 2025 Launches and Approvals Strengthen Its Oncology, Cardiovascular, and Respiratory Leadership Into 2026?
Global | January 2026 — AstraZeneca PLC achieved significant milestones in 2025, marked by multiple regulatory approvals, label…
Can Novo Nordisk’s 2025 Diabetes, Obesity, and Rare Disease Launches Drive Sustainable Growth Into 2026?
Global | January 2026 — Novo Nordisk A/S continued to reinforce its leadership in diabetes, obesity, and rare…
Can Roche’s 2025 Launches and Approvals Reinforce Its Leadership in Oncology, Diagnostics, and Neuroscience Into 2026?
Global | January 2026 — Roche Holding AG achieved a strong year in 2025, marked by multiple regulatory…
Roche Doubles Down on U.S. Biomanufacturing: $2 Billion Investment to Advance Next-Generation Therapies
23 January 2026 Executive Summary Roche’s Genentech unit announced a major expansion of its biomanufacturing facility in Holly…
Can Johnson & Johnson Hit $100 Billion in Revenue Despite U.S. Pricing Pressures?
23 January 2026 Executive Summary Johnson & Johnson (J&J) has issued a bullish 2026 revenue forecast, projecting nearly…
